5 CAR-T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote – Nasdaq
|
5 CAR–T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote
Nasdaq The CAR-T (chimeric antigen receptor T cells) space got a significant boost recently with an FDA advisory panel issuing a positive recommendation for an experimental treatment in this corner of the immune-oncology market. Last week, Swiss pharma giant, … |
